Journal
HUMAN GENE THERAPY
Volume 26, Issue 7, Pages 432-442Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/hum.2015.087
Keywords
-
Categories
Funding
- National Institutes of Health [5R00CA169512, P01AI100263, R01NS076991]
- National High Technology Research and Development Program (863 Program) of China [2012AA020810]
- Government of China
- Skoltech Center
- NIH Centers for Cancer Nanotechnology Excellence [5-U54-CA151884-04]
- Harvard-MIT Center of Cancer Nanotechnology Excellence
Ask authors/readers for more resources
CRISPR/Cas9 derived from the bacterial adaptive immunity pathway is a powerful tool for genome editing, but the safety profiles of in vivo delivered Cas9 (including host immune responses to the bacterial Cas9 protein) have not been comprehensively investigated in model organisms. Nonalcoholic steatohepatitis (NASH) is a prevalent human liver disease characterized by excessive fat accumulation in the liver. In this study, we used adenovirus (Ad) vector to deliver a Streptococcus pyogenes-derived Cas9 system (SpCas9) targeting Pten, a gene involved in NASH and a negative regulator of the PI3K-AKT pathway, in mouse liver. We found that the Ad vector mediated efficient Pten gene editing even in the presence of typical Ad vector-associated immunotoxicity in the liver. Four months after vector infusion, mice receiving the Pten gene-editing Ad vector showed massive hepatomegaly and features of NASH, consistent with the phenotypes following Cre-loxP-induced Pten deficiency in mouse liver. We also detected induction of humoral immunity against SpCas9 and the potential presence of an SpCas9-specific cellular immune response. Our findings provide a strategy to model human liver diseases in mice and highlight the importance considering Cas9-specific immune responses in future translational studies involving in vivo delivery of CRISPR/Cas9.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available